{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:18:29Z","timestamp":1791461909833,"version":"4.3.4"},"reference-count":235,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"unspecified","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,7,2]]},"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>Patients with advanced hepatocellular carcinoma (HCC) have historically had few options and faced extremely poor prognoses if their disease progressed after standard-of-care tyrosine kinase inhibitors (TKIs). Recently, the standard of care for HCC has been transformed as a combination of the immune checkpoint inhibitor (ICI) atezolizumab plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab was shown to offer improved overall survival in the first-line setting. Immunotherapy has demonstrated safety and efficacy in later lines of therapy as well, and ongoing trials are investigating novel combinations of ICIs and TKIs, in addition to interventions earlier in the course of disease or in combination with liver-directed therapies. Because HCC usually develops against a background of cirrhosis, immunotherapy for liver tumors is complex and oncologists need to account for both immunological and hepatological considerations when developing a treatment plan for their patients. To provide guidance to the oncology community on important concerns for the immunotherapeutic care of HCC, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). The expert panel drew on the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for HCC, including diagnosis and staging, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with HCC.<\/jats:p>","DOI":"10.1136\/jitc-2021-002794","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:05:15Z","timestamp":1631491515000},"page":"e002794","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":65,"title":["Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct01658878","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02702414","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01658878","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03298451","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0806-2535","authenticated-orcid":false,"given":"Tim F","family":"Greten","sequence":"first","affiliation":[{"name":"Thoracic and GI Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan K","family":"Abou-Alfa","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Weill Medical College at Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Lii","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin G","family":"Duffy","sequence":"additional","affiliation":[{"name":"The Mater Hospital\/University College Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony B.","family":"El-Khoueiry","sequence":"additional","affiliation":[{"name":"Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S","family":"Finn","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R","family":"Galle","sequence":"additional","affiliation":[{"name":"University of Mainz Medical Center, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lipika","family":"Goyal","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiwu Ruth","family":"He","sequence":"additional","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed O","family":"Kaseb","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin Kate","family":"Kelley","sequence":"additional","affiliation":[{"name":"Department of Medicine (Hematology\/Oncology), UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Lencioni","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Pisa School of Medicine, Pisa, Italy"},{"name":"Miami Cancer Institute, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaia","family":"Lujambio","sequence":"additional","affiliation":[{"name":"Oncological Sciences Department, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Mabry Hrones","sequence":"additional","affiliation":[{"name":"Thoracic and GI Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3529-0103","authenticated-orcid":false,"given":"David J","family":"Pinato","sequence":"additional","affiliation":[{"name":"Department of Surgery & Cancer, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Sangro","sequence":"additional","affiliation":[{"name":"Clinica Universidad de Navarra-Instituto de Investigaci\u00f3n Sanitaria de Navarra (IDISNA), Pamplona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto I","family":"Troisi","sequence":"additional","affiliation":[{"name":"Federico II University Naples, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Wilson Woods","sequence":"additional","affiliation":[{"name":"Blue Faery: The Adrienne Wilson Liver Cancer Association, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Yau","sequence":"additional","affiliation":[{"name":"Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew X","family":"Zhu","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"Jiahui Health, Jiahui International Cancer Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":false,"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[{"name":"Clinica Universidad de Navarra-Instituto de Investigaci\u00f3n Sanitaria de Navarra (IDISNA), Pamplona, Spain"},{"name":"Foundation for Applied Medical Research (FIMA), Pamplona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,9,12]]},"reference":[{"key":"2026052108101988000_9.9.e002794.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"2026052108101988000_9.9.e002794.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"2026052108101988000_9.9.e002794.3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29936"},{"key":"2026052108101988000_9.9.e002794.4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.12.061"},{"key":"2026052108101988000_9.9.e002794.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2007.02.006"},{"key":"2026052108101988000_9.9.e002794.6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24199"},{"key":"2026052108101988000_9.9.e002794.7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29913"},{"key":"2026052108101988000_9.9.e002794.8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/cld.782","article-title":"Treatment for advanced hepatocellular carcinoma: current standard and the future","volume":"13","author":"Likhitsup","year":"2019","journal-title":"Clin Liver Dis"},{"key":"2026052108101988000_9.9.e002794.9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cld.2011.03.002","article-title":"Systemic therapy in hepatocellular carcinoma","volume":"15","author":"Wrzesinski","year":"2011","journal-title":"Clin Liver Dis"},{"key":"2026052108101988000_9.9.e002794.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32453-9"},{"key":"2026052108101988000_9.9.e002794.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"2026052108101988000_9.9.e002794.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0073-4"},{"key":"2026052108101988000_9.9.e002794.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"2026052108101988000_9.9.e002794.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6"},{"key":"2026052108101988000_9.9.e002794.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4012"},{"key":"2026052108101988000_9.9.e002794.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"2026052108101988000_9.9.e002794.17","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0749-z"},{"key":"2026052108101988000_9.9.e002794.18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jhep.2017.09.007","article-title":"Targets for immunotherapy of liver cancer","volume":"68","author":"Greten","year":"2018","journal-title":"Journal of Hepatology"},{"key":"2026052108101988000_9.9.e002794.19","doi-asserted-by":"crossref","unstructured":"Graham R , Mancher M , et al, Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines . Clinical practice guidelines we can trust. US: National Academies Press, 2011.","DOI":"10.17226\/13058"},{"key":"2026052108101988000_9.9.e002794.20","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.213"},{"key":"2026052108101988000_9.9.e002794.21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy308"},{"key":"2026052108101988000_9.9.e002794.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.019"},{"key":"2026052108101988000_9.9.e002794.23","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13411"},{"key":"2026052108101988000_9.9.e002794.24","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2018181494"},{"key":"2026052108101988000_9.9.e002794.25","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1007\/s00261-018-1868-6","article-title":"CT\/MR LI-RADS 2018: clinical implications and management recommendations","volume":"44","author":"Kamath","year":"2019","journal-title":"Abdom Radiol"},{"key":"2026052108101988000_9.9.e002794.26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00261-015-0592-8","article-title":"Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma","volume":"41","author":"Hanna","year":"2016","journal-title":"Abdom Radiol"},{"key":"2026052108101988000_9.9.e002794.27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1148\/radiol.14140690","article-title":"Hepatocellular carcinoma: diagnostic performance of multidetector CT and Mr imaging-a systematic review and meta-analysis","volume":"275","author":"Lee","year":"2015","journal-title":"Radiology"},{"key":"2026052108101988000_9.9.e002794.28","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001157","article-title":"Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid (Gd-EOB-DTPA)-Enhanced Magnetic Resonance Imaging and Multidetector-Row Computed Tomography for the Diagnosis of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis","volume":"94","author":"Ye","year":"2015","journal-title":"Medicine"},{"key":"2026052108101988000_9.9.e002794.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.03.038"},{"key":"2026052108101988000_9.9.e002794.30","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.149062"},{"key":"2026052108101988000_9.9.e002794.31","doi-asserted-by":"crossref","first-page":"E31","DOI":"10.21037\/jgo.2015.12.01","article-title":"Acute myeloid leukemia masquerading as hepatocellular carcinoma","volume":"7","author":"Abu-Zeinah","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"2026052108101988000_9.9.e002794.32","doi-asserted-by":"crossref","unstructured":"Brierley JD , Gospodarowicz MK , Wittekind C . TNM classification of malignant tumours. John Wiley & Sons, 2017.","DOI":"10.1002\/9780471420194.tnmc26.pub3"},{"key":"2026052108101988000_9.9.e002794.33","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20034"},{"key":"2026052108101988000_9.9.e002794.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(98)80223-7"},{"key":"2026052108101988000_9.9.e002794.35","doi-asserted-by":"publisher","DOI":"10.1007\/s005350300038"},{"key":"2026052108101988000_9.9.e002794.36","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10384"},{"key":"2026052108101988000_9.9.e002794.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80173-1"},{"key":"2026052108101988000_9.9.e002794.38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2012.02811.x"},{"key":"2026052108101988000_9.9.e002794.39","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20636"},{"key":"2026052108101988000_9.9.e002794.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2009.03.054"},{"key":"2026052108101988000_9.9.e002794.41","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s00535-005-1751-4","article-title":"Modified Japan integrated staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy","volume":"41","author":"Nanashima","year":"2006","journal-title":"J Gastroenterol"},{"key":"2026052108101988000_9.9.e002794.42","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/cncr.25044","article-title":"Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models","volume":"116","author":"Hsu","year":"2010","journal-title":"Cancer"},{"key":"2026052108101988000_9.9.e002794.43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.9895"},{"key":"2026052108101988000_9.9.e002794.44","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800600817"},{"key":"2026052108101988000_9.9.e002794.45","first-page":"1","article-title":"Surgery and portal hypertension","volume":"1","author":"Child","year":"1964","journal-title":"Major Probl Clin Surg"},{"key":"2026052108101988000_9.9.e002794.46","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290145"},{"key":"2026052108101988000_9.9.e002794.47","first-page":"64","article-title":"Current management of advanced hepatocellular carcinoma","volume":"2","author":"Abou-Alfa","year":"2008","journal-title":"Gastrointest Cancer Res"},{"key":"2026052108101988000_9.9.e002794.48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.9151"},{"key":"2026052108101988000_9.9.e002794.49","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/COC.0000000000000384","article-title":"Assessment of the albumin-bilirubin (ALBI) grade as a prognostic indicator for hepatocellular carcinoma patients treated with radioembolization","volume":"41","author":"Gui","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"2026052108101988000_9.9.e002794.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.008"},{"key":"2026052108101988000_9.9.e002794.51","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00130-1"},{"key":"2026052108101988000_9.9.e002794.52","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-5-201203060-00012"},{"key":"2026052108101988000_9.9.e002794.53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228857"},{"key":"2026052108101988000_9.9.e002794.54","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400725"},{"key":"2026052108101988000_9.9.e002794.55","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00689-9"},{"key":"2026052108101988000_9.9.e002794.56","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3259"},{"key":"2026052108101988000_9.9.e002794.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.11.012"},{"key":"2026052108101988000_9.9.e002794.58","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-18-0281"},{"key":"2026052108101988000_9.9.e002794.59","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32206"},{"key":"2026052108101988000_9.9.e002794.60","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001033"},{"key":"2026052108101988000_9.9.e002794.61","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2021.04.047","article-title":"CheckMate 040 cohort 5: a phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis","author":"Kudo","year":"2021","journal-title":"J Hepatol"},{"key":"2026052108101988000_9.9.e002794.62","unstructured":"FDA . FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma. US: FDA, 2020."},{"key":"2026052108101988000_9.9.e002794.63","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.3_suppl.269","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (PTS) with advanced hepatocellular carcinoma (aHCC): long-term results from CheckMate 040","volume":"39","author":"El-Khoueiry","year":"2021","journal-title":"JCO"},{"key":"2026052108101988000_9.9.e002794.64","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz394.029"},{"key":"2026052108101988000_9.9.e002794.65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01307"},{"key":"2026052108101988000_9.9.e002794.66","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.3_suppl.267","article-title":"IMbrave150: updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (SOR) in patients (PTS) with unresectable hepatocellular carcinoma (HCC)","volume":"39","author":"Finn","year":"2021","journal-title":"JCO"},{"key":"2026052108101988000_9.9.e002794.67","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2337"},{"key":"2026052108101988000_9.9.e002794.68","doi-asserted-by":"crossref","unstructured":"Peter R , Cheng A-L , Bernaards C . CT185 - Assessment of the impact of anti-drug antibodies on PK and clinical outcomes with atezolizumab + bevacizumab in HCC. AACR Annual Meeting, 2021.","DOI":"10.1158\/1538-7445.AM2021-CT185"},{"key":"2026052108101988000_9.9.e002794.69","doi-asserted-by":"crossref","unstructured":"Abou-Alfa GK , Lau G , Kudo M , et al . Tremelimumab plus Durvalumab in Unresectable hepatocellular carcinoma. NEJM Evidence 2022;1. doi:10.1056\/EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070"},{"key":"2026052108101988000_9.9.e002794.70","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J Hepatol"},{"key":"2026052108101988000_9.9.e002794.71","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS3110","article-title":"A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma","volume":"36","author":"Qin","year":"2018","journal-title":"JCO"},{"key":"2026052108101988000_9.9.e002794.72","doi-asserted-by":"crossref","first-page":"viii719","DOI":"10.1093\/annonc\/mdy424.029","article-title":"A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment","volume":"29","author":"Qin","year":"2018","journal-title":"Ann Oncol"},{"key":"2026052108101988000_9.9.e002794.73","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.4071","article-title":"Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC)","volume":"35","author":"Wainberg","year":"2017","journal-title":"JCO"},{"key":"2026052108101988000_9.9.e002794.74","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.4_suppl.478","article-title":"Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (Cabo) combination therapy in patients (PTS) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040","volume":"38","author":"Yau","year":"2020","journal-title":"JCO"},{"key":"2026052108101988000_9.9.e002794.75","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026052108101988000_9.9.e002794.76","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4152","article-title":"Lenvatinib (LEN) plus pembrolizumab (pembro) for the first-line treatment of patients (PTS) with advanced hepatocellular carcinoma (HCC): phase 3 LEAP-002 study","volume":"37","author":"Llovet","year":"2019","journal-title":"JCO"},{"key":"2026052108101988000_9.9.e002794.77","doi-asserted-by":"crossref","unstructured":"Kudo M , Motomura K , Wada Y . First-Line avelumab+ axitinib in patients with advanced hepatocellular carcinoma: results from a phase 1B trial (VEGF liver 100). J Clin Oncol 2019;35.","DOI":"10.1200\/JCO.2019.37.15_suppl.4072"},{"key":"2026052108101988000_9.9.e002794.78","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4157","article-title":"Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (a) versus sorafenib (S) in patients (PTS) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy","volume":"37","author":"Kelley","year":"2019","journal-title":"JCO"},{"key":"2026052108101988000_9.9.e002794.79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.01.027"},{"key":"2026052108101988000_9.9.e002794.80","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"2026052108101988000_9.9.e002794.81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.01.027"},{"key":"2026052108101988000_9.9.e002794.82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.10.012"},{"key":"2026052108101988000_9.9.e002794.83","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.3.1914"},{"key":"2026052108101988000_9.9.e002794.84","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol"},{"key":"2026052108101988000_9.9.e002794.85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.10.029"},{"key":"2026052108101988000_9.9.e002794.86","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70284-5"},{"key":"2026052108101988000_9.9.e002794.87","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-10-209","article-title":"A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma","volume":"10","author":"Greten","year":"2010","journal-title":"BMC Cancer"},{"key":"2026052108101988000_9.9.e002794.88","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0585-1"},{"key":"2026052108101988000_9.9.e002794.89","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1129483","article-title":"Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients","volume":"5","author":"Sawada","year":"2016","journal-title":"Oncoimmunology"},{"key":"2026052108101988000_9.9.e002794.90","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3044"},{"key":"2026052108101988000_9.9.e002794.91","first-page":"5902","article-title":"T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer","volume":"9","author":"Butterfield","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2026052108101988000_9.9.e002794.92","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.8.5300"},{"key":"2026052108101988000_9.9.e002794.93","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3748\/wjg.v11.i5.700","article-title":"Tumor vaccine against recurrence of hepatocellular carcinoma","volume":"11","author":"Peng","year":"2005","journal-title":"World J Gastroenterol"},{"key":"2026052108101988000_9.9.e002794.94","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2856"},{"key":"2026052108101988000_9.9.e002794.95","doi-asserted-by":"crossref","first-page":"2","DOI":"10.20517\/2394-5079.2019.25","article-title":"Interim results from ongoing phase III placebo-controlled, randomized trial of hepcortespenlisimut-L for advanced hepatocellular carcinoma indication","volume":"2020","author":"Bourinbaiar","year":"2020","journal-title":"Hepatoma Res"},{"key":"2026052108101988000_9.9.e002794.96","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22626"},{"key":"2026052108101988000_9.9.e002794.97","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol Cancer"},{"key":"2026052108101988000_9.9.e002794.98","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS3135","article-title":"HepaVac-101 first-in-man therapeutic cancer vaccine phase I\/II clinical trial for hepatocellular carcinoma patients","volume":"36","author":"Buonaguro","year":"2018","journal-title":"JCO"},{"key":"2026052108101988000_9.9.e002794.99","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01335-5"},{"key":"2026052108101988000_9.9.e002794.100","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.174.1.139","article-title":"Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity","volume":"174","author":"Schmidt-Wolf","year":"1991","journal-title":"J Exp Med"},{"key":"2026052108101988000_9.9.e002794.101","first-page":"1673","article-title":"Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells","volume":"21","author":"Schmidt-Wolf","year":"1993","journal-title":"Exp Hematol"},{"key":"2026052108101988000_9.9.e002794.102","doi-asserted-by":"publisher","DOI":"10.1084\/jem.174.1.139"},{"key":"2026052108101988000_9.9.e002794.103","doi-asserted-by":"crossref","DOI":"10.1186\/2162-3619-1-11","article-title":"Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety","volume":"1","author":"Ma","year":"2012","journal-title":"Exp Hematol Oncol"},{"key":"2026052108101988000_9.9.e002794.104","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.02.055"},{"key":"2026052108101988000_9.9.e002794.105","doi-asserted-by":"crossref","first-page":"81967","DOI":"10.18632\/oncotarget.17804","article-title":"Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"key":"2026052108101988000_9.9.e002794.106","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1007\/s10620-007-9750-3","article-title":"Causes of death in patients with unresectable hepatocellular carcinoma","volume":"52","author":"Couto","year":"2007","journal-title":"Dig Dis Sci"},{"key":"2026052108101988000_9.9.e002794.107","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-018-1194-4","article-title":"Patient performance status and cancer immunotherapy efficacy: a meta-analysis","volume":"35","author":"Bersanelli","year":"2018","journal-title":"Med Oncol"},{"key":"2026052108101988000_9.9.e002794.108","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-007-9750-3"},{"key":"2026052108101988000_9.9.e002794.109","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1159\/000511001","article-title":"Recent advances in systemic therapy for hepatocellular carcinoma in an aging Society: 2020 update","volume":"9","author":"Kudo","year":"2020","journal-title":"Liver Cancer"},{"key":"2026052108101988000_9.9.e002794.110","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1200\/JCO.2012.48.4857","article-title":"Contraindicated use of bevacizumab and toxicity in elderly patients with cancer","volume":"31","author":"Hershman","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026052108101988000_9.9.e002794.111","doi-asserted-by":"publisher","DOI":"10.1159\/000511001"},{"key":"2026052108101988000_9.9.e002794.112","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4857"},{"key":"2026052108101988000_9.9.e002794.113","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1200\/JCO.18.00885","article-title":"Influence of HIV infection on the natural history of hepatocellular carcinoma: results from a global Multicohort study","volume":"37","author":"Pinato","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026052108101988000_9.9.e002794.114","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-a phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026052108101988000_9.9.e002794.115","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Cao M , Moran T , Dalmau J . Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected. J Clin Oncol 2019;39.doi:10.1200\/JCO.2019.37.15_suppl.2501","DOI":"10.1200\/JCO.2019.37.15_suppl.2501"},{"key":"2026052108101988000_9.9.e002794.116","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000356","article-title":"Immunotherapy to treat malignancy in patients with pre-existing autoimmunity","volume":"8","author":"Boland","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026052108101988000_9.9.e002794.117","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2073"},{"key":"2026052108101988000_9.9.e002794.118","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000356"},{"key":"2026052108101988000_9.9.e002794.119","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2073"},{"key":"2026052108101988000_9.9.e002794.120","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"2026052108101988000_9.9.e002794.121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9380","article-title":"The causes and effects of socio-demographic exclusions from clinical trials","volume":"9","author":"Bartlett","year":"2005","journal-title":"Health Technol Assess"},{"key":"2026052108101988000_9.9.e002794.122","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.05.039"},{"key":"2026052108101988000_9.9.e002794.123","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.4599","article-title":"Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC","volume":"38","author":"Kaseb","year":"2020","journal-title":"JCO"},{"key":"2026052108101988000_9.9.e002794.124","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001918"},{"key":"2026052108101988000_9.9.e002794.125","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.3_suppl.335","article-title":"Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC)","volume":"39","author":"Yarchoan","year":"2021","journal-title":"JCO"},{"key":"2026052108101988000_9.9.e002794.126","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-981-10-5765-6_2","article-title":"Hepatitis B virus-associated hepatocellular carcinoma","volume":"1018","author":"Xie","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"2026052108101988000_9.9.e002794.127","doi-asserted-by":"crossref","DOI":"10.20517\/2394-5079.2019.15","article-title":"Management of concomitant hepatocellular carcinoma and chronic hepatitis C: a review","volume":"2019","author":"Harrod","year":"2019","journal-title":"Hepatoma Res"},{"key":"2026052108101988000_9.9.e002794.128","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0771-1","article-title":"Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection","volume":"7","author":"Shah","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026052108101988000_9.9.e002794.129","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01037","article-title":"Anti-Pd-1\/Pd-L1 blockade immunotherapy employed in treating hepatitis B virus infection-related advanced hepatocellular carcinoma: a literature review","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"key":"2026052108101988000_9.9.e002794.130","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0771-1"},{"key":"2026052108101988000_9.9.e002794.131","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000394","article-title":"Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma","volume":"8","author":"Ho","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026052108101988000_9.9.e002794.132","doi-asserted-by":"crossref","unstructured":"Richard Finn S S , MasafumiIkeda PRG , Ducreux M . IMbrave150: updated efficacy and safety by risk status in patients (PTS) receiving Atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (HCC). AACR Annual Meeting, 2021.","DOI":"10.1158\/1538-7445.AM2021-CT009"},{"key":"2026052108101988000_9.9.e002794.133","unstructured":"FDA . TECENTRIQ highlights of prescribing information. Drugs@FDA"},{"key":"2026052108101988000_9.9.e002794.134","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30937-9"},{"key":"2026052108101988000_9.9.e002794.135","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1016\/j.annonc.2020.04.078","article-title":"LBA-3 CheckMate 459: long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma","volume":"31","author":"Sangro","year":"2020","journal-title":"Ann of Oncol"},{"key":"2026052108101988000_9.9.e002794.136","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30937-9"},{"key":"2026052108101988000_9.9.e002794.137","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","article-title":"\u03b2-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma","volume":"9","author":"Ruiz de Galarreta","year":"2019","journal-title":"Cancer Discov"},{"key":"2026052108101988000_9.9.e002794.138","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0510"},{"key":"2026052108101988000_9.9.e002794.139","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0074"},{"key":"2026052108101988000_9.9.e002794.140","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2293"},{"key":"2026052108101988000_9.9.e002794.141","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.1113","article-title":"997P PD-L1 protein expression as a predictor of response to immune checkpoint inhibitor (ICI) in hepatocellular carcinoma (HCC): a meta-analysis","volume":"31","author":"Wang","year":"2020","journal-title":"Ann Oncol"},{"key":"2026052108101988000_9.9.e002794.142","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.07.026"},{"key":"2026052108101988000_9.9.e002794.143","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an Immune-specific class of hepatocellular carcinoma, based on molecular features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"2026052108101988000_9.9.e002794.144","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(18)30249-6","article-title":"Hepatic safety and biomarker assessments in sorafenib-experienced patients with advanced hepatocellular carcinoma treated with nivolumab in the CheckMate-040 study","volume":"68","author":"Meyer","year":"2018","journal-title":"J Hepatol"},{"key":"2026052108101988000_9.9.e002794.145","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.4508","article-title":"Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (PTS) with advanced hepatocellular carcinoma (aHCC)","volume":"38","author":"Kelley","year":"2020","journal-title":"JCO"},{"key":"2026052108101988000_9.9.e002794.146","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"Pd-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"2026052108101988000_9.9.e002794.147","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"2026052108101988000_9.9.e002794.148","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02107"},{"key":"2026052108101988000_9.9.e002794.149","doi-asserted-by":"crossref","unstructured":"Rugo HS , Delord J-P , Im S-A . Safety and antitumor activity of pembrolizumab in patients with estrogen receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer. Clin Cancer Res.doi:10.1158\/1078-0432.CCR-17-3452","DOI":"10.1158\/1078-0432.CCR-17-3452"},{"key":"2026052108101988000_9.9.e002794.150","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02105"},{"key":"2026052108101988000_9.9.e002794.151","unstructured":"US FDA . FDA approves pembrolizumab for adults and children with TMB-H solid tumors [press release]. Drug Approvals and Databases, 2020."},{"key":"2026052108101988000_9.9.e002794.152","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111798","article-title":"Tumor mutational burden and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"11","author":"Kim","year":"2019","journal-title":"Cancers"},{"key":"2026052108101988000_9.9.e002794.153","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111798"},{"key":"2026052108101988000_9.9.e002794.154","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0458"},{"key":"2026052108101988000_9.9.e002794.155","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26998"},{"key":"2026052108101988000_9.9.e002794.156","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgh035"},{"key":"2026052108101988000_9.9.e002794.157","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1097\/MEG.0000000000001405","article-title":"Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib","volume":"31","author":"Hong","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026052108101988000_9.9.e002794.158","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1002\/cam4.3135","article-title":"Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy","volume":"9","author":"Dharmapuri","year":"2020","journal-title":"Cancer Med"},{"key":"2026052108101988000_9.9.e002794.159","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3135"},{"key":"2026052108101988000_9.9.e002794.160","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.02.007"},{"key":"2026052108101988000_9.9.e002794.161","doi-asserted-by":"publisher","DOI":"10.1038\/nature12347"},{"key":"2026052108101988000_9.9.e002794.162","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706"},{"key":"2026052108101988000_9.9.e002794.163","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy103"},{"key":"2026052108101988000_9.9.e002794.164","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0650-9","article-title":"Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma","volume":"7","author":"Zheng","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026052108101988000_9.9.e002794.165","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0650-9"},{"key":"2026052108101988000_9.9.e002794.166","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.clnu.2015.08.005","article-title":"The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma","volume":"35","author":"Rollins","year":"2016","journal-title":"Clin Nutr"},{"key":"2026052108101988000_9.9.e002794.167","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24183214","article-title":"Sex differences in cancer immunotherapy efficacy, biomarkers, and therapeutic strategy","volume":"24","author":"Wang","year":"2019","journal-title":"Molecules"},{"key":"2026052108101988000_9.9.e002794.168","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-018-1467-x","article-title":"Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade","volume":"16","author":"Valpione","year":"2018","journal-title":"J Transl Med"},{"key":"2026052108101988000_9.9.e002794.169","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1467-x"},{"key":"2026052108101988000_9.9.e002794.170","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10391"},{"key":"2026052108101988000_9.9.e002794.171","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0081-1"},{"key":"2026052108101988000_9.9.e002794.172","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0245"},{"key":"2026052108101988000_9.9.e002794.173","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S126227"},{"key":"2026052108101988000_9.9.e002794.174","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s40425-019-0779-6","article-title":"Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis","volume":"7","author":"Xing","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026052108101988000_9.9.e002794.175","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0779-6"},{"key":"2026052108101988000_9.9.e002794.176","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)31347-7"},{"key":"2026052108101988000_9.9.e002794.177","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435"},{"key":"2026052108101988000_9.9.e002794.178","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","article-title":"Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"72","author":"Sangro","year":"2020","journal-title":"J Hepatol"},{"key":"2026052108101988000_9.9.e002794.179","unstructured":"Organization WH . WHO Handbook for reporting results of cancer treatment. World Health Organization, 1979."},{"key":"2026052108101988000_9.9.e002794.180","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"2026052108101988000_9.9.e002794.181","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"2026052108101988000_9.9.e002794.182","doi-asserted-by":"publisher","DOI":"10.1148\/rg.336135511"},{"key":"2026052108101988000_9.9.e002794.183","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn134"},{"key":"2026052108101988000_9.9.e002794.184","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1247132"},{"key":"2026052108101988000_9.9.e002794.185","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/annonc\/mds605","article-title":"mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)","volume":"24","author":"Prajapati","year":"2013","journal-title":"Ann Oncol"},{"key":"2026052108101988000_9.9.e002794.186","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds605"},{"key":"2026052108101988000_9.9.e002794.187","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jhep.2017.01.012","article-title":"Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC","volume":"66","author":"Lencioni","year":"2017","journal-title":"J Hepatol"},{"key":"2026052108101988000_9.9.e002794.188","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.01.012"},{"key":"2026052108101988000_9.9.e002794.189","doi-asserted-by":"crossref","DOI":"10.1186\/s41747-019-0134-1","article-title":"Imaging of tumour response to immunotherapy","volume":"4","author":"Dromain","year":"2020","journal-title":"Eur Radiol Exp"},{"key":"2026052108101988000_9.9.e002794.190","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1200\/EDBK_200643","article-title":"Patterns of response and progression to immunotherapy","volume":"38","author":"Borcoman","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026052108101988000_9.9.e002794.191","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20112674","article-title":"Hyperprogression under immunotherapy","volume":"20","author":"Frelaut","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026052108101988000_9.9.e002794.192","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2217\/imt-2018-0126","article-title":"Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series","volume":"11","author":"Wong","year":"2019","journal-title":"Immunotherapy"},{"key":"2026052108101988000_9.9.e002794.193","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jhep.2020.09.025","article-title":"Hyperprogression in hepatocellular carcinoma: illusion or reality?","volume":"74","author":"Chan","year":"2021","journal-title":"J Hepatol"},{"key":"2026052108101988000_9.9.e002794.194","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/annonc\/mdl065","article-title":"Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma","volume":"17","author":"Yeo","year":"2006","journal-title":"Ann Oncol"},{"key":"2026052108101988000_9.9.e002794.195","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl065"},{"key":"2026052108101988000_9.9.e002794.196","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-008-9365-y"},{"key":"2026052108101988000_9.9.e002794.197","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.11.019"},{"key":"2026052108101988000_9.9.e002794.198","doi-asserted-by":"publisher","DOI":"10.1002\/pon.1022"},{"key":"2026052108101988000_9.9.e002794.199","doi-asserted-by":"publisher","DOI":"10.1002\/1099-1611(200101\/02)10:1<19::AID-PON501>3.0.CO;2-6"},{"key":"2026052108101988000_9.9.e002794.200","unstructured":"Squibb B-M . U.S. survey of liver cancer caregivers. 24 Jul 2017 \u2013 31 Aug 2017, 2017."},{"key":"2026052108101988000_9.9.e002794.201","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s10903-011-9523-0","article-title":"Hepatitis B and liver cancer among three Asian American sub-groups: a focus group inquiry","volume":"14","author":"Philbin","year":"2012","journal-title":"J Immigr Minor Health"},{"key":"2026052108101988000_9.9.e002794.202","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/705094","article-title":"The impact of hepatitis B knowledge and stigma on screening in Canadian Chinese persons","volume":"26","author":"Li","year":"2012","journal-title":"Can J Gastroenterol"},{"key":"2026052108101988000_9.9.e002794.203","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.jceh.2014.03.049","article-title":"Role of supportive care for terminal stage hepatocellular carcinoma","volume":"4","author":"Kumar","year":"2014","journal-title":"J Clin Exp Hepatol"},{"key":"2026052108101988000_9.9.e002794.204","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.clinthera.2018.02.017","article-title":"Palliative care for people with hepatocellular carcinoma, and specific benefits for older adults","volume":"40","author":"Woodrell","year":"2018","journal-title":"Clin Ther"},{"key":"2026052108101988000_9.9.e002794.205","doi-asserted-by":"crossref","first-page":"e1190","DOI":"10.1634\/theoncologist.2018-0820","article-title":"Balancing the hype with reality: what do patients with advanced melanoma consider when making the decision to have immunotherapy?","volume":"24","author":"Wong","year":"2019","journal-title":"Oncologist"},{"key":"2026052108101988000_9.9.e002794.206","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0820"},{"key":"2026052108101988000_9.9.e002794.207","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1016\/j.cgh.2019.03.022","article-title":"Barriers to use of palliative care and advance care planning discussions for patients with end-stage liver disease","volume":"17","author":"Ufere","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026052108101988000_9.9.e002794.208","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cgh.2013.11.010","article-title":"Palliative care and end-stage liver disease","volume":"12","author":"Walling","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026052108101988000_9.9.e002794.209","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.cgh.2013.08.027","article-title":"Patients with cirrhosis and denied liver transplants rarely receive adequate palliative care or appropriate management","volume":"12","author":"Poonja","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026052108101988000_9.9.e002794.210","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1634\/theoncologist.2016-0419","article-title":"Safety and tolerability of PD-1\/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis","volume":"22","author":"Nishijima","year":"2017","journal-title":"Oncologist"},{"key":"2026052108101988000_9.9.e002794.211","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0419"},{"key":"2026052108101988000_9.9.e002794.212","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-13-0404"},{"key":"2026052108101988000_9.9.e002794.213","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2013.001217"},{"key":"2026052108101988000_9.9.e002794.214","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/j.ejca.2004.06.033","article-title":"Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18","volume":"40","author":"Blazeby","year":"2004","journal-title":"Eur J Cancer"},{"key":"2026052108101988000_9.9.e002794.215","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.06.033"},{"key":"2026052108101988000_9.9.e002794.216","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.093"},{"key":"2026052108101988000_9.9.e002794.217","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(02)00422-0"},{"key":"2026052108101988000_9.9.e002794.218","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.cgh.2010.03.008","article-title":"Health-Related quality of life in patients with hepatocellular carcinoma: a systematic review","volume":"8","author":"Fan","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026052108101988000_9.9.e002794.219","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.03.008"},{"key":"2026052108101988000_9.9.e002794.220","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MEG.0b013e32834ec184","article-title":"Illness experience in patients with hepatocellular carcinoma: an interpretative phenomenological analysis study","volume":"24","author":"Fan","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026052108101988000_9.9.e002794.221","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/pon.3146","article-title":"Health-related quality of life in patients with hepatocellular carcinoma: the mediation effects of illness perceptions and coping","volume":"22","author":"Fan","year":"2013","journal-title":"Psychooncology"},{"key":"2026052108101988000_9.9.e002794.222","doi-asserted-by":"publisher","DOI":"10.1002\/pon.3146"},{"key":"2026052108101988000_9.9.e002794.223","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.dld.2009.09.002","article-title":"Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal","volume":"42","author":"Trevisani","year":"2010","journal-title":"Dig Liver Dis"},{"key":"2026052108101988000_9.9.e002794.224","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2009.09.002"},{"key":"2026052108101988000_9.9.e002794.225","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cld.711","article-title":"Pain management in patients with cirrhosis","volume":"11","author":"Rakoski","year":"2018","journal-title":"Clin Liver Dis"},{"key":"2026052108101988000_9.9.e002794.226","doi-asserted-by":"crossref","first-page":"166","DOI":"10.21037\/atm.2018.03.28","article-title":"Financial toxicity and implications for cancer care in the era of molecular and immune therapies","volume":"6","author":"Tran","year":"2018","journal-title":"Ann Transl Med"},{"key":"2026052108101988000_9.9.e002794.227","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/phar.1867","article-title":"Rising cost of cancer pharmaceuticals: cost issues and interventions to control costs","volume":"37","author":"Glode","year":"2017","journal-title":"Pharmacotherapy"},{"key":"2026052108101988000_9.9.e002794.228","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/jamaoncol.2015.0373","article-title":"Five years of cancer drug approvals: innovation, efficacy, and costs","volume":"1","author":"Mailankody","year":"2015","journal-title":"JAMA Oncol"},{"key":"2026052108101988000_9.9.e002794.229","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1634\/theoncologist.2012-0279","article-title":"The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience","volume":"18","author":"Zafar","year":"2013","journal-title":"Oncologist"},{"key":"2026052108101988000_9.9.e002794.230","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0279"},{"key":"2026052108101988000_9.9.e002794.231","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.0468"},{"key":"2026052108101988000_9.9.e002794.232","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2013.001322"},{"key":"2026052108101988000_9.9.e002794.233","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.4_suppl.476","article-title":"Patient-Reported outcomes (pros) from the phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (SOR) as first-line treatment (tx) for patients (PTS) with unresectable hepatocellular carcinoma (HCC)","volume":"38","author":"Galle","year":"2020","journal-title":"JCO"},{"key":"2026052108101988000_9.9.e002794.234","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/cncr.33317","article-title":"Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240","volume":"127","author":"Ryoo","year":"2021","journal-title":"Cancer"},{"key":"2026052108101988000_9.9.e002794.235","unstructured":"(Liver) ACoRCoL-R . Liver reporting & data system (LI-RADS): American college of Radiology. liver reporting & data system (LI-RADS). n.d."}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-002794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:10:48Z","timestamp":1779376248000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-002794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":235,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,12]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1136\/jitc-2021-002794"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-002794","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}